In 2008, forensic scientists from Western Australia's ChemCentre stumbled upon something entirely unexpected while investigating a clandestine drug lab—a pile of wet bark stripped from a wattle tree and stewed in a makeshift extraction setup. That discovery opened a window onto a peculiar intersection of Australian ecology, chemistry, and criminal enterprise: the nation's iconic wattle trees contain DMT, a powerful psychedelic compound, and enterprising criminals had figured out how to extract and sell it on Perth's streets.
The DMT-producing acacias are so common in Western Australia that nearly 900 species grow across the state alone, making them an abundant and accessible source for illegal extraction. Today, forensics teams find more plant mulch in drug labs than methamphetamine residue, a striking reversal that speaks to how widespread the practice has become. Yet not all wattle trees contain the drug—and understanding which ones do reveals something deeper about plant chemistry and what we still don't know about the natural world.
Dr. Kelly Shepherd, Senior Research Scientist at the WA Herbarium and one of only two botanists in the state authorized to work with illegal drugs, became the go-to expert for identifying mystery bark samples recovered from labs. When she and her colleagues at ChemCentre drug-tested hundreds of preserved plant samples from the herbarium's collection of over 845,000 specimens, they discovered that only a handful of acacia species actually produce DMT. "The only other species that contained DMT were close relatives of the species we already knew about," Shepherd explained, suggesting the compound was likely a chance mutation passed down from a common ancestor rather than anything that spoke to some hidden significance in the plant itself.
What struck Shepherd more than the presence of the chemical was what it revealed about the gaps in human knowledge. "These plants in the middle of nowhere have these interesting substances in them and we don't even know," she noted, echoing a broader argument about why biodiversity matters—we cannot predict what undiscovered compounds or properties might be waiting in species we haven't yet fully studied.
Meanwhile, on the legitimate research side, scientists have begun exploring DMT's potential as medicine rather than street drug. Last year, Daniel Perkins, an associate professor at the University of Melbourne's Psychedelics Research and Therapeutics Unit, published the first clinical trial using DMT extracted from Australian acacia plants in a controlled CSIRO facility. Nine healthy volunteers who had prior experience with psychedelics reported that DMT produced experiences remarkably similar to ayahuasca, the plant brew traditionally used in South American ceremonies.
The mechanism is elegant: LSD, psilocybin, and DMT all work primarily through the same serotonin receptor in the brain, triggering a cascade of effects—increased connectivity between brain areas that don't usually communicate, suppression of rigid belief structures, and alterations in the default mode network that governs our sense of self. For researchers like Perkins, these effects hold promise not for recreation but for treating trauma, alcohol use disorder, and severe depression where conventional treatments have failed.
Yet clinical development will rely on synthetic DMT, not the plant itself. Wattle contains only 0.5 to 1.5 percent of the compound by weight, meaning extraction requires processing vast quantities of plant material—something Perkins dismisses as impractical for global medicine. His team's next trial, launching later this year, will test DMT's efficacy for alcohol use disorder and major depressive disorder, moving psychedelic therapy incrementally closer to the clinic while the wattle trees of Western Australia remain largely overlooked.